Journal Mobile Options
Table of Contents
Vol. 118, No. 3, 2007
Issue release date: October 2007
Acta Haematol 2007;118:141–145

Safety of Imatinib in Chronic Myeloid Leukemia in Blastic Crisis Presenting as Cholestatic Jaundice

Ramamoorthy S.K. · Pandita R. · Prakash A. · Ramaswamy N.V. · Al Bahar S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Acute leukemia presenting as cholestatic jaundice is rare. It can occur due to granulocytic sarcoma compressing the bile ducts in case of acute myeloid leukemia. Rarely, diffuse infiltration of the liver sinusoids by the leukemic blasts can present as cholestatic jaundice. We report a case of chronic myeloid leukemia in lymphoid blast cell crisis presenting with severe cholestatic jaundice due to diffuse infiltration of the liver sinusoids with lymphoblasts. This patient tolerated imatinib well and, coinciding with the hematological response, there was marked reduction in the cholestasis due to blast clearance from the hepatic sinusoids. He was subsequently treated with combination chemotherapy and achieved morphological and cytogenetic remission.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Corpechot C, Lemann M, Brocheriou I, Mariette X, Bonnet J, Daniel MT, Bertheau P, Lavergne A, Modigliani R: Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. Am J Gastroenterol 1998;93:2586–2588.
  2. Goor Y, Goor O, Michalewitz F, Cabili S: Acute myeloid leukemia presenting as obstructive jaundice. J Clin Gastroenterol 2002;34:485–486.
  3. King DJ, Ewen SW, Sewell HF, Dawson AA: Obstructive jaundice: an unusual presentation of granulocytic sarcoma. Cancer 1987;60:114–117.
  4. Wandroo FA, Murray M, Mutimer D, Hubscher S: Acute myeloid leukemia presenting as cholestatic hepatitis. J Clin Pathol 2004;57:544–545.
  5. Phadke AY, Shah SK, Narawane NM, Abraham P: Acute lymphoblastic leukemia presenting with severe jaundice in an adult. J Assoc Physicians India 1999;47:240–241.
  6. Druker BJ, Sawyers C, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdiville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1043.
  7. Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ: Results of treatment with hyper-CVAD, a dose-intensive regimen in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547–561.
  8. Thomas DA, Faderl S, Cortes J, O’Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreef M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.
  9. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809–1820.
  10. Product Information: Gleevec™, imatinib mesylate. East Hanover, Novartis Pharmaceuticals, 2001.
  11. Lyseng-Williamson K, Jarvis B: Imatinib. Drugs 2001;61:1765–1774.
  12. De Pas T, Danesi R, Catania C, Curigliano G, De Braud F: Imatinib administration in two patients with liver metastases from GIST and severe jaundice. Br J Cancer 2003;89:1403–1404.
  13. Bauer S, Hagen V, Pielken HJ, Bolko P, Seeber S, Schutte J: Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 2002;13:847–849.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50